Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer



Status:Completed
Conditions:Lung Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:6/2/2017
Start Date:September 2013
End Date:May 4, 2017

Use our guide to learn which trials are right for you!

Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer

The purpose of this study is to determine the maximum tolerated dose and assess the safety,
tolerability and activity of carfilzomib given in combination with carboplatin and etoposide
as initial therapy for subjects with Extensive-Stage Small-Cell Lung Cancer (ES SCLC).


Key Inclusion Criteria:

1. Histologically or cytologically confirmed diagnosis of extensive-stage small-cell
lung cancer (ES-SCLC) with measurable disease per Response Evaluation Criteria in
Solid Tumors (RECIST) Version 1.1; ES-SCLC is defined as: small-cell lung cancer
(SCLC) that has spread beyond one hemithorax and regional lymph nodes on the same
side (e.g., supraclavicular) to the contralateral hemithorax, lymph nodes, or more
distant locations in the body

2. Subjects with asymptomatic brain metastases or other central nervous system (CNS)
disease at screening/diagnosis are eligible

3. Males and females ≥ 18 years of age

4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

Key Exclusion Criteria:

1. Previous systemic therapy to treat small-cell lung cancer (SCLC). Subjects with
recurrent or progressive limited-stage SCLC after previous systemic treatment are not
eligible for study participation.

2. Whole brain or focal radiation therapy within 14 days prior to Cycle 1 Day 1 (C1D1)
for Phase 1b or prior to randomization for Phase 2

3. Congestive heart failure (New York Heart Association [NYHA] class III to IV),
symptomatic ischemia, conduction abnormalities uncontrolled by conventional
intervention, or myocardial infarction within 6 months prior to prior to C1D1 for
Phase 1b or prior to randomization for Phase 2
We found this trial at
12
sites
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
Charlotte, North Carolina 28211
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Frederick, Maryland 21701
?
mi
from
Frederick, MD
Click here to add this to my saved trials
Goshen, Indiana 46526
?
mi
from
Goshen, IN
Click here to add this to my saved trials
Hackensack, New Jersey 07601
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Hamilton, Ontario
?
mi
from
Hamilton,
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Lafayette, Indiana
?
mi
from
Lafayette, IN
Click here to add this to my saved trials
?
mi
from
Lexington, KY
Click here to add this to my saved trials
?
mi
from
Muncie, IN
Click here to add this to my saved trials
New Haven, Connecticut 06520
?
mi
from
New Haven, CT
Click here to add this to my saved trials
Winston-Salem, North Carolina 27157
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials